abacavir and Lymphoma--AIDS-Related

Topics: Alopecia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD8-Positive T-Lymphocytes; Clone Cells; Dideoxynucleosides; Drug Therapy, Combination; Humans; Immunophenotyping; Lamivudine; Lymphoma, AIDS-Related; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Remission Induction; Ritonavir

A 38-year-old HIV positive man suffered from right upper abdominal pain and oesophageal reflux syndromes. He was in a good general state of health and nutrition with no concomitant symptoms.. A small bowel tumor and slight soor esophagitis had been diagnosed by esophago-gastroduodenoscopy. The tumor was histologically classified as Burkitt?s lymphoma.. The patient received 6 cycles of chemotherapy according to the B-ALL protocol, and antiretroviral therapy with lamivudine (300 mg), abacavir (600 mg) und raltegravir (2 × 400 mg) was initiated immediately. After the first cycle of chemotherapy a complete remission of Burkitt?s lymphoma was achieved. Laboratory parameters recovered after completion of 6 cycles to a value of 400 CD4-positive lymphocytes/mm (3) with a viral load of HIV-1-RNA 20 - 300 copies/ml in plasma.. Immediate initiation of antiretroviral therapy is essential after the diagnosis of AIDS-defining symptoms. The choice of an appropriate treatment regimen is a critical factor in order to avoid toxic drug interactions and adverse events while maintaining a highly effective treatment.

Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; CD4 Lymphocyte Count; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenal Neoplasms; HIV Seropositivity; Humans; Intestine, Small; Lamivudine; Lymphoma, AIDS-Related; Male; Pyrrolidinones; Raltegravir Potassium; Remission Induction; Viral Load